A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma

Ibrutinib is a first‐in‐class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallace, Natalie, Wong, Ellice, Cooper, Dennis, Chao, Herta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134133/
https://www.ncbi.nlm.nih.gov/pubmed/27980745
http://dx.doi.org/10.1002/ccr3.719
_version_ 1782471409543413760
author Wallace, Natalie
Wong, Ellice
Cooper, Dennis
Chao, Herta
author_facet Wallace, Natalie
Wong, Ellice
Cooper, Dennis
Chao, Herta
author_sort Wallace, Natalie
collection PubMed
description Ibrutinib is a first‐in‐class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia.
format Online
Article
Text
id pubmed-5134133
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-51341332016-12-15 A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma Wallace, Natalie Wong, Ellice Cooper, Dennis Chao, Herta Clin Case Rep Case Reports Ibrutinib is a first‐in‐class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia. John Wiley and Sons Inc. 2016-10-17 /pmc/articles/PMC5134133/ /pubmed/27980745 http://dx.doi.org/10.1002/ccr3.719 Text en © 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Wallace, Natalie
Wong, Ellice
Cooper, Dennis
Chao, Herta
A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
title A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
title_full A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
title_fullStr A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
title_full_unstemmed A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
title_short A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
title_sort case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134133/
https://www.ncbi.nlm.nih.gov/pubmed/27980745
http://dx.doi.org/10.1002/ccr3.719
work_keys_str_mv AT wallacenatalie acaseofnewonsetcardiomyopathyandventriculartachycardiainapatientreceivingibrutinibforrelapsedmantlecelllymphoma
AT wongellice acaseofnewonsetcardiomyopathyandventriculartachycardiainapatientreceivingibrutinibforrelapsedmantlecelllymphoma
AT cooperdennis acaseofnewonsetcardiomyopathyandventriculartachycardiainapatientreceivingibrutinibforrelapsedmantlecelllymphoma
AT chaoherta acaseofnewonsetcardiomyopathyandventriculartachycardiainapatientreceivingibrutinibforrelapsedmantlecelllymphoma
AT wallacenatalie caseofnewonsetcardiomyopathyandventriculartachycardiainapatientreceivingibrutinibforrelapsedmantlecelllymphoma
AT wongellice caseofnewonsetcardiomyopathyandventriculartachycardiainapatientreceivingibrutinibforrelapsedmantlecelllymphoma
AT cooperdennis caseofnewonsetcardiomyopathyandventriculartachycardiainapatientreceivingibrutinibforrelapsedmantlecelllymphoma
AT chaoherta caseofnewonsetcardiomyopathyandventriculartachycardiainapatientreceivingibrutinibforrelapsedmantlecelllymphoma

Ejemplares similares